Kainova Therapeutics

France
Illkirch-Graffenstaden, Grand Est, France

Company profile

Kainova Therapeutics company profile

Kainova Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), one of the best classes of drug targets. Domain Therapeutics is using its innovative and proprietary technology platform DTect-All™ to identify orthosteric and allosteric ligands of GPCRs, including the so called Silent Allosteric Modulators (SAMs) that represent a unique source of compounds that cannot be discovered by standard technologies. DTect-All™ is able to address difficult GPCRs such as orphan and peptidic GPCRs.

Business identity

Contact email
[email protected]
Phone number
+33 3 90 40 61 50
Operating status
Active
Company type
For Profit
Employee range
101-250 employees
Revenue range
$0-$1M
Founded
2001-01-01, Year

Headquarters

Country code
FR
Continent
Europe

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
11
Total equity funding
$105.8M
Last funding
Series B / $23.5M / 2026-02-09
Last equity funding
Series B / $23.5M
Investors
26
Lead investors
6
Founders
1
Articles
50

Founders and investors

Founders

Pascal Neuville

Lead investors

3B Future Health FundCTI Life Sciences FundInvestissement QuebecPanacea VentureSeventure PartnersSofinnova Partners

Investors

Andera PartnersBpifranceSchroders CapitalSeventure PartnersSofinnova Partners